Fascioliasis
📧 Sign up to get email alerts when something new happens for Fascioliasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older). [Phase 4]
A Phase 4 clinical trial evaluating the safety, tolerability, and clinical outcomes of Egaten (triclabendazole) in Fascioliasis patients age…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis [Phase 2]
A Phase 2 clinical trial compares one and two doses of oxfendazole to two doses of triclabendazole for chronic fascioliasis; the study statu…
-
FDA approval · 2022-02-17FDA Approved: EGATEN — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for EGATEN (triclabendazole) from Novartis Pharmaceuticals Corporation. The action approves a su…
-
FDA approval · 2019-02-13FDA Approved: EGATEN — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved EGATEN (triclabendazole) under an original NDA from Novartis Pharmaceuticals Corporation. The approval is for the treatment…